70406-92-7

Usage

Uses

Anagrelide impurity A.

InChI:InChI=1/C11H14Cl2N2O2/c1-2-17-10(16)6-15-5-7-9(14)4-3-8(12)11(7)13/h3-4,15H,2,5-6,14H2,1H3

Upstream product

• 70380-51-7 3,4-dichloro-2-hydroxymethylaniline 
• 623-33-6 glycine ethyl ester hydrochloride 
• 70380-50-6 N-(2,3-dichloro-6-nitrobenzyl)glycine ethyl ester hydrochloride 
• 1677-47-0 4,5-Dichloro-1H-indole-2,3-dione 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 146374-56-3 ethyl (2-cyanoimino-5,6-dichloro-1,2,3,4-tetrahydroquinazolin-3-yl)-acetate 
• 4455-13-4 methylthioacetic acid ethyl ester 
• 200571-11-5 2-cyanoimino-5,6-dichloro-1,2,3,4-tetrahydroquinazoline 
• 58579-51-4 anagrelide hydrochloride 
• 146374-56-3 ethyl-(2-cyanoimino-5,6-dichloro-1,2,3,4-tetrahydroquinazolin-3-yl) acetate 
• 70381-75-8 ethyl-5,6-dichloro-3,4-dihydro-2-(1H)-iminoquinazoline-3-acetate hydrobromide 
• 68475-42-3 anagrelide 

Relevant academic research and scientific papers

Process for the Manufacture of Anagrelide Hydrochloride Monohydrate

The present invention relates to a process for preparation of Anagrelide Hydrochloride Monohydrate.

PROCESS FOR THE PREPARATION OF ETHYL-N-(2, 3-DICHLORO-6-NITROBENZYL) GLYCINE HYDROCHLORIDE

The invention relates to a process for the preparation of anagrelide, and for the preparation of intermediates for use in preparing anagrelide. The invention also relates to the inte?nediates per se, in particular compounds of formula (V) where R constitutes a suitable leaving group, which may not be hydrogen. The R group may be is selected from: (i) -SiR1 3, (ii) -CH2Ar, (iii) -COOR2, and (iv) sulfonates such as -SO2R3.

Alkyl 5,6-dichloro-3,4-dihydro-2(1H)-iminoquinazoline-3-acetate hydrohalides

The known blood platelet antiaggregative agent 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one is prepared in high yield via an improved process involving a novel intermediate of the Formula STR1 in which R1 is (lower)alkyl and X is bromo, chloro or iodo. Two processes for the preparation of compounds of the Formula III are disclosed, one of which involves the novel intermediate STR2